A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.
Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.
ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.